Crinetics Highlights Breakout Year and Strong Endocrinology Pipeline

Crinetics Pharmaceuticals ( (CRNX) ) just unveiled an update.

On January 13, 2026, Crinetics Pharmaceuticals’ founder and CEO Scott Struthers presented a company update at the 44th annual J.P. Morgan Healthcare Conference in San Francisco, highlighting 2025 as a breakout year in which the company launched PALSONIFY (paltusotine) commercially in the U.S., reported early signs of market uptake, and advanced its strategy to become a leading endocrinology-focused pharmaceutical business. The update emphasized a late-stage pipeline of potentially transformative assets, including paltusotine for additional indications such as carcinoid syndrome, atumelnant for adult and pediatric congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome, and CRN09682 for neuroendocrine and other SST2+ tumors, supported by positive Phase 2 data, initiation of multiple Phase 3 and Phase 1/2 studies, and a strong preliminary and unaudited liquidity position of roughly $1.4 billion in cash, cash equivalents and investments as of early January 2026, positioning the company to fund operations and development programs well into the next decade.

The most recent analyst rating on (CRNX) stock is a Buy with a $67.00 price target. To see the full list of analyst forecasts on Crinetics Pharmaceuticals stock, see the CRNX Stock Forecast page.

Spark’s Take on CRNX Stock

According to Spark, TipRanks’ AI Analyst, CRNX is a Neutral.

Overall score is held back primarily by weak current financial performance (minimal revenue alongside large losses and heavy cash burn). Offsetting this are a strong balance sheet and funding outlook, plus constructive launch/pipeline updates from the earnings call and corporate events. Technical signals are mixed and valuation is difficult to support with a negative P/E and no dividend.

To see Spark’s full report on CRNX stock, click here.

More about Crinetics Pharmaceuticals

Crinetics Pharmaceuticals is a biopharmaceutical company focused on endocrinology, developing and commercializing oral therapies for endocrine diseases, including PALSONIFY (paltusotine) for acromegaly and a late-stage pipeline targeting carcinoid syndrome, congenital adrenal hyperplasia, ACTH-dependent Cushing’s syndrome and neuroendocrine tumors. The company is building a fully integrated pharmaceutical infrastructure, advancing multiple Phase 3 and earlier-stage programs, and pursuing partnering opportunities for additional endocrine-related assets and nonpeptide therapeutics.

Average Trading Volume: 1,410,035

Technical Sentiment Signal: Buy

Current Market Cap: $5.46B

Learn more about CRNX stock on TipRanks’ Stock Analysis page.